Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Abstract

There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Until recently, the biological role of PPAR beta/delta remained unclear. However, treatment of obese animals by specific PPAR delta agonists results in normalization of metabolic parameters and reduction of adiposity. Combined treatments with PPAR gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies "pure" PPAR gamma ligands. The new generation of dual-action PPARs--the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) are on deck in late-stage clinical trials and may be effective in reducing cardiovascular risk, but their long-term clinical effects are still unknown. A number of glitazars have presented problems at a late stage of clinical trials because of serious side-effects (including ragaglitazar and farglitazar). The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan--(alpha, beta/delta, gamma) PPAR activator. It is the only pan-PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile. Therefore, bezafibrate could be considered (indeed, as a "post hoc" understanding) as an "archetype" of a clinically tested pan-PPAR ligand. Bezafibrate leads to considerable raising of HDL cholesterol and reduces triglycerides, improves insulin sensitivity and reduces blood glucose level, significantly lowering the incidence of cardiovascular events and new diabetes in patients with features of metabolic syndrome. Clinical evidences obtained from bezafibrate-based studies strongly support the concept of pan-PPAR therapeutic approach to conditions which comprise the metabolic syndrome. However, from a biochemical point of view, bezafibrate is a PPAR ligand with a relatively low potency. More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders.

• Authors: Alexander Tenenbaum, Michael Motro, Enrique Z Fisman
• Journal: Cardiovascular diabetology (Cardiovasc Diabetol) Vol. 4 Pg. 14 (Sep 16 2005) ISSN: 1475-2840 [Electronic] England
• PMID: 16168052 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Cholesterol, HDL
• Hypolipidemic Agents
• PPAR alpha
• PPAR delta
• PPAR gamma
• Peroxisome Proliferator-Activated Receptors
• Triglycerides
• Bezafibrate

Topics

• Bezafibrate (adverse effects, therapeutic use)
• Cardiovascular Diseases (prevention & control)
• Cholesterol, HDL (blood)
• Coronary Disease (prevention & control)
• Diabetes Mellitus, Type 2 (prevention & control)
• Humans
• Hyperlipidemias (drug therapy)
• Hypolipidemic Agents
• Male
• Middle Aged
• Myocardial Infarction (prevention & control)
• PPAR alpha (physiology)
• PPAR delta (physiology)
• PPAR gamma (physiology)
• Peroxisome Proliferator-Activated Receptors (agonists, physiology)
• Triglycerides (blood)